PL2919780T3 - Pochodne 1,3-dihydroimidazolo-2-tionu do zastosowania w leczeniu tętniczego nadciśnienia płucnego i uszkodzenia płuc - Google Patents

Pochodne 1,3-dihydroimidazolo-2-tionu do zastosowania w leczeniu tętniczego nadciśnienia płucnego i uszkodzenia płuc

Info

Publication number
PL2919780T3
PL2919780T3 PL13803292T PL13803292T PL2919780T3 PL 2919780 T3 PL2919780 T3 PL 2919780T3 PL 13803292 T PL13803292 T PL 13803292T PL 13803292 T PL13803292 T PL 13803292T PL 2919780 T3 PL2919780 T3 PL 2919780T3
Authority
PL
Poland
Prior art keywords
dihydroimidazole
treatment
lung injury
arterial hypertension
pulmonary arterial
Prior art date
Application number
PL13803292T
Other languages
English (en)
Polish (pl)
Inventor
Patrício Manuel Vieira Araújo SOARES DA SILVA
Maria João Macedo da Silva BONIFÁCIO
Original Assignee
Bial - Portela & Ca., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial - Portela & Ca., S.A. filed Critical Bial - Portela & Ca., S.A.
Publication of PL2919780T3 publication Critical patent/PL2919780T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13803292T 2012-11-14 2013-11-14 Pochodne 1,3-dihydroimidazolo-2-tionu do zastosowania w leczeniu tętniczego nadciśnienia płucnego i uszkodzenia płuc PL2919780T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
EP13803292.5A EP2919780B1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (1)

Publication Number Publication Date
PL2919780T3 true PL2919780T3 (pl) 2019-01-31

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13803292T PL2919780T3 (pl) 2012-11-14 2013-11-14 Pochodne 1,3-dihydroimidazolo-2-tionu do zastosowania w leczeniu tętniczego nadciśnienia płucnego i uszkodzenia płuc

Country Status (23)

Country Link
US (3) US9604970B2 (OSRAM)
EP (1) EP2919780B1 (OSRAM)
JP (1) JP6373275B2 (OSRAM)
KR (1) KR102259938B1 (OSRAM)
CN (1) CN105025895B (OSRAM)
AU (1) AU2013345494B2 (OSRAM)
BR (1) BR112015010969B1 (OSRAM)
CA (1) CA2890920C (OSRAM)
CY (1) CY1120953T1 (OSRAM)
DK (1) DK2919780T3 (OSRAM)
ES (1) ES2693025T3 (OSRAM)
HR (1) HRP20181651T1 (OSRAM)
IN (1) IN2015DN04089A (OSRAM)
LT (1) LT2919780T (OSRAM)
MX (1) MX355422B (OSRAM)
PL (1) PL2919780T3 (OSRAM)
PT (1) PT2919780T (OSRAM)
RS (1) RS57874B1 (OSRAM)
RU (1) RU2718055C2 (OSRAM)
SI (1) SI2919780T1 (OSRAM)
SM (1) SMT201800560T1 (OSRAM)
TR (1) TR201815850T4 (OSRAM)
WO (1) WO2014077715A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN04089A (OSRAM) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
HUT76295A (en) * 1994-04-26 1997-07-28 Syntex Inc Imidazolyl- and triazolyl-thion derivatives, pharmaceutical compositions containing them and process for producing them
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
EP2231648A1 (en) * 2007-12-05 2010-09-29 BIAL - Portela & Ca., S.A. New salts and crystal forms
JP2011508775A (ja) * 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
IN2015DN04089A (OSRAM) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A

Also Published As

Publication number Publication date
EP2919780B1 (en) 2018-08-01
MX2015005910A (es) 2015-08-10
CY1120953T1 (el) 2020-05-29
BR112015010969B1 (pt) 2020-05-26
AU2013345494B2 (en) 2018-03-22
IN2015DN04089A (OSRAM) 2015-10-09
HRP20181651T1 (hr) 2018-12-14
US10308640B2 (en) 2019-06-04
MX355422B (es) 2018-04-18
CN105025895A (zh) 2015-11-04
US20190241545A1 (en) 2019-08-08
RU2015120164A (ru) 2017-01-10
CN105025895B (zh) 2019-02-26
SI2919780T1 (sl) 2018-12-31
DK2919780T3 (en) 2018-11-26
EP2919780A1 (en) 2015-09-23
TR201815850T4 (tr) 2018-11-21
PT2919780T (pt) 2018-11-13
RU2718055C2 (ru) 2020-03-30
JP6373275B2 (ja) 2018-08-15
WO2014077715A1 (en) 2014-05-22
CA2890920C (en) 2020-12-15
KR20150084022A (ko) 2015-07-21
JP2016504286A (ja) 2016-02-12
ES2693025T3 (es) 2018-12-07
SMT201800560T1 (it) 2019-01-11
BR112015010969A2 (pt) 2017-08-22
HK1215393A1 (en) 2016-08-26
RS57874B1 (sr) 2018-12-31
AU2013345494A1 (en) 2015-05-14
KR102259938B1 (ko) 2021-06-03
US20170369477A1 (en) 2017-12-28
US20150299172A1 (en) 2015-10-22
LT2919780T (lt) 2018-11-12
CA2890920A1 (en) 2014-05-22
US9604970B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
IL223241A0 (en) Cysteamine derivatives and their use in the treatment of nash
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
SG11201401716XA (en) Novel purine derivatives and their use in the treatment of disease
IL237649B (en) Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint
EP2841064A4 (en) USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF DISEASES AND INJURIES
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
SMT201800560T1 (it) Derivati di 1,3-diidroimidazol-2-tione per uso nel trattamento di ipertensione arteriosa polmonare e lesione del polmone
PL2861568T3 (pl) Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
PT2699545T (pt) Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico
IL228891A0 (en) Use of 3-carboxy-m-ethyl n,n--dimethylpropane-1-aminium salts in the treatment of cardiovascular disease
ZA201307847B (en) 4-(haldalkyl)(dimethyl) ammonio) butandates and use thereof in the treatment of cardiovascular disease
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis